Anxiety Disorder

Segui
UCSF researcher Jennifer Mitchell in a lab examining MM120, an LSD-based drug for treating generalized anxiety disorder.
Immagine generata dall'IA

UCSF researchers test LSD-based MM120 for generalized anxiety disorder

Riportato dall'IA Immagine generata dall'IA Verificato

UCSF neuroscientist Jennifer Mitchell and collaborators are evaluating MM120, a pharmaceutical form of LSD, as a potential treatment for generalized anxiety disorder. A randomized clinical trial published in JAMA found that a single dose reduced anxiety symptoms versus placebo, with benefits persisting up to 12 weeks in the optimal dose group, according to the study and the drug’s sponsor.

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta